Edinburgh Molecular Imaging Limited is a clinical phase biotechnology company that focuses on enabling image guided interventional medicine, it has a molecular targetting technology that has the potential to fight disease instantly to enable interventional procedures including surgery and therapy, providing more accurate treatment while sparing healthy tissue.
Edinburgh Molecular Imaging focuses on the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes or radionuclides, target and specifically bind with cancerous cells and other diseased tissues. Its approach provides clinician with a clearer view of the extent of disease and a decision-making tool to benefit patients.
Edinburgh Molecular Imaging comprises of a team with decades of success in imaging agent amd therapeutics discovery and development, with expertise spanning from radiochemistry, medicinal chemistry, biochemistry and cell biology, together with clinical expertise. The team has important expertise in the clinical development, approval and reimbursement of molecular imaging and therapeutic agents. The company aims to become a leader in offering targeted fluorescent optical imaging and therapy agents as an accessible imaging modality.